SAN FRANCISCO, July 3 /PRNewswire-FirstCall/ -- Medivation, Inc. today announced that it will hold a teleconference at 5:00 p.m. EDT on Monday, July 7, to discuss top-line results from its randomized, double-blind, placebo-controlled Phase 2 clinical trial of dimebon(TM) in Huntington’s disease.
Teleconference/Webcast Details
To participate in the live call on Monday, July 7, at 5:00 p.m. Eastern time by telephone, please dial 877-419-6590 from the U.S. or 719-325-4860 internationally. A telephone replay will be available until July 9 at midnight following the conclusion of the call by dialing 888-203-1112 from the U.S. or 719-457-0820 for international callers and entering passcode 4109873. Individuals interested in listening to the live call via webcast may do so by visiting http://www.medivation.com. A replay of the webcast will be available on the Company’s website for 30 days.
About Medivation
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases of the central nervous system and cancers for which there are limited treatment options. Medivation aims to revolutionize the treatment of these diseases and offer hope to critically ill patients and their caregivers. The Company’s current clinical development program includes a pivotal and confirmatory Phase 3 trial of dimebon(TM) in Alzheimer’s disease, a Phase 2 clinical trial of dimebon in patients with Huntington’s disease, and a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer. For more information, please visit us at http://www.medivation.com.
This press release contains forward-looking statements, including statements regarding anticipated clinical and regulatory milestones, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to differ significantly from those projected. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. None of the Company’s product candidates has been approved for sale, significant additional animal and human testing is required in order to seek marketing approval for any of its product candidates, and Medivation cannot assure you that marketing approval can be obtained for any of its product candidates. Furthermore, as is typically the case at this stage of the regulatory review process, the FDA has not yet performed an in-depth review of Medivation’s preclinical and clinical data, so its views remain subject to change. Medivation’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the year ended December 31, 2007 and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2008, include information about additional factors that could affect the Company’s financial and operating results.
CONTACT: Patrick Machado, Chief Financial Officer of Medivation, Inc.,
+1-415-829-4101; or Monique Greer of WeissComm Partners, +1-415-946-1075,
for Medivation, Inc.
Web site: http://www.medivation.com/
